{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:28:59Z","timestamp":1793348939040,"version":"4.5.0"},"reference-count":29,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000867","name":"Robert Wood Johnson Foundation","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100000867","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH","award":["K23-HL155890"],"award-info":[{"award-number":["K23-HL155890"]}]},{"name":"NIH","award":["P50-CA140158"],"award-info":[{"award-number":["P50-CA140158"]}]},{"name":"NIH","award":["R01HL168045"],"award-info":[{"award-number":["R01HL168045"]}]},{"name":"NIH","award":["R01HL170038"],"award-info":[{"award-number":["R01HL170038"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,1,22]]},"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bispecific T-cell engagers (BTEs) are novel agents used to treat hematological malignancies. Early trials were underpowered to define cardiovascular adverse events (CVAE) and no large-scale studies systematically examined the CVAEs associated with BTEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Leveraging the US Food and Drug Administration\u2019s Adverse Event Reporting System-(FAERS), we identified the relative frequency of CVAEs after initiation of five BTE products approved by the Food and Drug Administration between 2014 and 2023 for the treatment of hematological malignancies. Adjusted reporting ORs (aROR) were used to identify disproportionate reporting of CVAEs with BTEs compared with background rates in the database. Fatality rates and risk ratios (RRs) for each adverse event (AE) were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 3668 BTE-related cases reported to FAERS, 747 (20.4%) involved CVAEs. BTEs as a class were associated with fatal CVAEs (aROR 1.29 (95% CI 1.12 to 1.50)), an association mainly driven by teclistamab (aROR 2.44 (95% CI 1.65 to 3.60)). Teclistamab was also associated with a disproportionate risk of myocarditis (aROR 25.70 (95% CI 9.54 to 69.23)) and shock (aROR 3.63 (95% CI 2.30 to 5.74)), whereas blinatumomab was associated with a disproportionate risk of disseminated intravascular coagulation (aROR 3.02 (95% CI 1.98 to 4.60)) and hypotension (aROR 1.59 (95% CI 1.25 to 2.03)). CVAEs were more fatal compared with non-CVAEs (31.1% vs 17.4%; RR 1.76 (95% CI 1.54 to 2.03)). Most CVAEs (83.3%) did not overlap with cytokine release syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In the first postmarketing surveillance study of BTEs, CVAEs were involved in approximately one in five AE reports and carried a significant mortality risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2023-008518","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T01:50:11Z","timestamp":1708566611000},"page":"e008518","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":38,"title":["Cardiovascular toxicities associated with bispecific T-cell engager therapy"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0150-8917","authenticated-orcid":false,"given":"Ahmed","family":"Sayed","sequence":"first","affiliation":[{"name":"Ain Shams University Faculty of Medicine, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak","family":"Munir","sequence":"additional","affiliation":[{"name":"Ain Shams University Faculty of Medicine, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanam M","family":"Ghazi","sequence":"additional","affiliation":[{"name":"The Ohio State University Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mussammat","family":"Ferdousi","sequence":"additional","affiliation":[{"name":"The Ohio State University Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyam","family":"Krishan","sequence":"additional","affiliation":[{"name":"University of Oklahoma Medical Center, City, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Shaaban","sequence":"additional","affiliation":[{"name":"The Ohio State University Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Habib","sequence":"additional","affiliation":[{"name":"The Ohio State University Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onaopepo","family":"Kola-Kehinde","sequence":"additional","affiliation":[{"name":"The Ohio State University Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Ruz","sequence":"additional","affiliation":[{"name":"The Ohio State University Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Khan","sequence":"additional","affiliation":[{"name":"The Ohio State University Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Sharma","sequence":"additional","affiliation":[{"name":"The Ohio State University Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Meara","sequence":"additional","affiliation":[{"name":"The Ohio State University Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Mahmood","sequence":"additional","affiliation":[{"name":"Catholic Health Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Feldman","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H","family":"Yang","sequence":"additional","affiliation":[{"name":"Medicine, UCLA Medical Center, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Kim","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[{"name":"The Ohio State University Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Addison","sequence":"additional","affiliation":[{"name":"The Ohio State University Medical Center, Columbus, Ohio, USA"},{"name":"Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Ohio State University, Columbus, Ohio, USA"},{"name":"Division of Epidemiology, College of Public Health, Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"2025100311223798000_12.2.e008518.1","doi-asserted-by":"crossref","unstructured":"Goekbuget N , Dombret H , Bonifacio M , et al . BLAST: A Confirmatory, single-arm, phase 2 study of Blinatumomab, a Bispecific T-cell Engager (bite\u00ae) antibody construct, in patients with minimal residual disease B-precursor acute Lymphoblastic leukemia (ALL). Blood 2014;124. doi:10.1182\/blood.V124.21.379.379","DOI":"10.1182\/blood.V124.21.379.379"},{"key":"2025100311223798000_12.2.e008518.2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1609783"},{"key":"2025100311223798000_12.2.e008518.3","unstructured":"Drugs@FDA [database on the Internet]. U.S. Food and Drug Administration . Drug approval package Blincyto (blinatumomab) injection, Available: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125557Orig1s000TOC.cfm"},{"key":"2025100311223798000_12.2.e008518.4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies \u2014 bites and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100311223798000_12.2.e008518.5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2203478"},{"key":"2025100311223798000_12.2.e008518.6","unstructured":"FDA APPROVES Teclistamab-Cqyv for Relapsed or refractory multiple myeloma. n.d. Available: URL: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma"},{"key":"2025100311223798000_12.2.e008518.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"2025100311223798000_12.2.e008518.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"2025100311223798000_12.2.e008518.9","doi-asserted-by":"crossref","unstructured":"Derache A-F , Rialland F , Michel G , et al . Safety and efficacy of Blinatumomab used in children with B-precursor acute Lymphoblastic leukemia (ALL) treated in French hematological centers. Blood 2016;128. doi:10.1182\/blood.V128.22.5190.5190","DOI":"10.1182\/blood.V128.22.5190.5190"},{"key":"2025100311223798000_12.2.e008518.10","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of Blinatumomab in pediatric patients with Relapsed\/refractory acute Lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"JCO"},{"key":"2025100311223798000_12.2.e008518.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322"},{"key":"2025100311223798000_12.2.e008518.12","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of Blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute Lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"key":"2025100311223798000_12.2.e008518.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.10.038"},{"key":"2025100311223798000_12.2.e008518.14","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.bbmt.2020.08.036","article-title":"Cardiovascular events associated with Chimeric antigen receptor T cell therapy: cross-sectional FDA adverse events reporting system analysis","volume":"26","author":"Guha","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025100311223798000_12.2.e008518.15","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric antigen receptor T-cell therapy\u2013associated cardiomyopathy in patients with refractory or Relapsed non-Hodgkin lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"key":"2025100311223798000_12.2.e008518.16","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with Chimeric antigen receptor T-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025100311223798000_12.2.e008518.17","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/eurheartj\/ehad117","article-title":"Biomarkers and cardiovascular outcomes in Chimeric antigen receptor T-cell therapy recipients","volume":"44","author":"Mahmood","year":"2023","journal-title":"Eur Heart J"},{"key":"2025100311223798000_12.2.e008518.18","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-Blinatumomab for pH-positive acute Lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"key":"2025100311223798000_12.2.e008518.19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00277-018-3495-2","article-title":"Efficacy and safety of Blinatumomab treatment in adult Korean patients with Relapsed\/refractory acute Lymphoblastic leukemia on behalf of the Korean society of hematology ALL working party","volume":"98","author":"Jung","year":"2019","journal-title":"Ann Hematol"},{"key":"2025100311223798000_12.2.e008518.20","unstructured":"Food and Drug Administration . FDA Aes reporting system (FAERS) public dashboard. n.d. Available: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files"},{"key":"2025100311223798000_12.2.e008518.21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF03256752","article-title":"Meddra","volume":"23","author":"Mozzicato","year":"2009","journal-title":"Pharm Med"},{"key":"2025100311223798000_12.2.e008518.22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.1954"},{"key":"2025100311223798000_12.2.e008518.23","unstructured":"R Core Team . R: A language and environment for statistical computing. In: R Foundation for Statistical Computing. Vienna, Austria, 2022. Available: https:\/\/www.R-project.org"},{"key":"2025100311223798000_12.2.e008518.24","unstructured":"Dowle M , Srinivasan A . Data.table: Extension of 'data.frame'. R package version 1.14.2, 2021. Available: https:\/\/CRAN.R-project.org\/package=data.table"},{"key":"2025100311223798000_12.2.e008518.25","unstructured":"Arel-Bundock V . marginaleffects: Predictions, Comparisons, Slopes, Marginal Means, and Hypothesis Tests. R package version 0.13.0, Available: https:\/\/CRAN.R-project.org\/package=marginaleffects"},{"key":"2025100311223798000_12.2.e008518.26","doi-asserted-by":"crossref","unstructured":"Wickham H . Ggplot2. In: ggplot2: Elegant Graphics for Data Analysis. Cham: Springer-Verlag New York, 2016. doi:10.1007\/978-3-319-24277-4","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"2025100311223798000_12.2.e008518.27","doi-asserted-by":"crossref","unstructured":"Chen L-R , Li Y-J , Zhang Z , et al . Cardiovascular effects associated with Chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis. Front Oncol 2022;12. doi:10.3389\/fonc.2022.924208","DOI":"10.3389\/fonc.2022.924208"},{"key":"2025100311223798000_12.2.e008518.28","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","article-title":"Mechanisms of cardiovascular toxicities associated with Immunotherapies","volume":"128","author":"Baik","year":"2021","journal-title":"Circ Res"},{"key":"2025100311223798000_12.2.e008518.29","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1182\/bloodadvances.2022007454","article-title":"Relative Hypercoagulation induced by suppressed Fibrinolysis after Tisagenlecleucel infusion in malignant lymphoma","volume":"6","author":"Yamasaki-Morita","year":"2022","journal-title":"Blood Adv"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-008518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:22:49Z","timestamp":1759515769000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-008518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,21]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/jitc-2023-008518"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-008518","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}